Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies |
| |
Authors: | Arlene D Stark Shaun Jordan Kelly A Allers Robert L Bertekap Ruoyan Chen Tanaz Mistry Kannan Thaddeus F Molski Frank D Yocca Trevor Sharp Tetsuro Kikuchi Kevin D Burris |
| |
Institution: | (1) Neuroscience Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA;(2) Otsuka Maryland Research Institute, Inc., Rockville, MD, USA;(3) Department of Pharmacology, Oxford University, Oxford, UK;(4) Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan;(5) Palatin Technologies, Cranbury, NJ 08512, USA |
| |
Abstract: | Background Aripiprazole (7-{4-4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydro-2(1H)-quinolinone) is a novel antipsychotic with a mechanism of action that differs from current typical and atypical antipsychotics.
Aripiprazole interacts with a range of receptors, including serotonin 5-hydroxytryptamine (5-HT)] and dopamine receptors.
Materials and methods This study examined aripiprazole’s interactions with 5-HT systems in vitro and in vivo to further clarify its pharmacologic
properties.
Results Aripiprazole produced increases in 35S]GTPγS binding to rat hippocampal membranes. Its potency (pEC50 = 7.2) was similar to that of ziprasidone (7.1) and greater than that of 5-HT (6.7) and buspirone (6.4), a 5-HT1A-receptor partial agonist, whereas its intrinsic activity was similar to that of ziprasidone and buspirone. The stimulatory
effect of aripiprazole was blocked by WAY-100635, a 5-HT1A-receptor antagonist. In in vivo electrophysiology studies, aripiprazole produced a dose-related reduction in the firing
rate of 5-HT-containing dorsal raphe neurons in rats, which was both prevented and reversed by WAY-100635 administration.
Aripiprazole showed a high affinity for human 5-HT1A receptors (K
i = 4.2 nM) using parietal cortex membrane preparations. In membranes from cells expressing human recombinant receptors, aripiprazole
bound with high affinity to 5-HT2A receptors (K
i = 3.4 nM), moderate affinity to 5-HT2C (K
i = 15 nM) and 5-HT7 (K
i = 39 nM) receptors, and low affinity to 5-HT6 receptors (K
i = 214 nM) and 5-HT transporter (K
i = 98 nM). In addition, aripiprazole potently blocked 5-HT2A-receptor-mediated increases in intracellular Ca2+ levels in a rat pituitary cell line (IC50 = 11 nM).
Discussion These results support a partial agonist activity for aripiprazole at 5-HT1A receptors in vitro and in vivo, and suggest important interactions with other 5-HT-receptor subtypes. This receptor activity
profile may contribute to the antipsychotic activity of aripiprazole in humans. |
| |
Keywords: | Aripiprazole Dopamine Serotonin Schizophrenia Partial agonist Antagonist |
本文献已被 PubMed SpringerLink 等数据库收录! |
|